This story originally ran on Feb. 23.

By Adam Bonislawski

Integrated Diagnostics said this week it has secured the third $10 million tranche of its Series A funding upon achieving key milestones in its diagnostic programs.

Specifically, the company has completed clinical trials demonstrating the commercial potential of its proteomic lung cancer diagnostic, InDi CEO and director Albert Luderer told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.